Trends in Pharmacological Sciences
ReviewNucleoside transporters: from scavengers to novel therapeutic targets
Section snippets
The biological significance of nucleoside distribution and uptake
Nucleoside molecules are formed by the combination of a purine or pyrimidine nitrogenous base with a pentose sugar, either ribose or 2-deoxyribose. Purine and pyrimidine nucleosides are crucial for prokaryotic and eukaryotic biology. As the precursors to nucleotides (e.g. ATP) and nucleic acids, they indirectly support strategic processes, including energy provision, protein synthesis and cell replication. As ligands to widely distributed cell-surface purine P1 receptors, they have direct
Identification and characterization of nucleoside transport proteins
Mammalian genomes encode multiple representatives of two structurally unrelated nucleoside transporter families, the equilibrative nucleoside transporters [ENT1–4: Human Genome Organisation (HUGO: http://www.hugo-international.org/) nomenclature SLC29A1-4] [1] and the concentrative nucleoside transporters (CNT1–3: HUGO nomenclature SLC28A1-3) [2]. The ENT family is restricted to eukaryotes, whereas CNT family members are also found in eubacteria (Figure 1). Their names reflect the properties of
The physiological and therapeutic significance of CNS nucleoside transporters
Under conditions of metabolic or physiological stress (e.g. cerebral ischaemia, inflammation and seizure), elevated levels of adenosine trigger retaliatory homeostatic and neuromodulatory actions that protect against neuronal damage [21]. Even in normal physiology, however, adenosine exerts a wide-ranging influence on peripheral and central neurons via G-protein-coupled P1 A1, A2A, A2B and A3 receptors [22]. Intracellular or extracellular adenosine formed, for example, as a result of
Nucleoside transporters as therapeutic targets in disease and infection
Nucleoside analogue drugs (NADs) and nucleoside transporter inhibitors represent a powerful addition to the armamentarium of frontline drugs used to combat the devastating effects of chronic diseases, including those caused by RNA viruses, cancer and parasitic protozoan infection. Advances in the efficacy of NAD-based therapies are inextricably linked to a more detailed profiling of the cellular distributions, transport kinetics and substrate selectivities of the ENT and CNT families. A
Nucleoside transporters as potential targets for antiparasitic drugs
Most parasites that infect humans lack de novo pathways for purine nucleotide synthesis and, thus, rely on the uptake of purine nucleosides and nucleobases from the host for salvage synthesis of these key metabolites. Members of the ENT family have key roles in such purine uptake in the protozoa that are responsible for many important human diseases, including malaria (Plasmodium spp.), sleeping sickness (Trypanosoma spp.) and leishmaniasis (Leishmania spp.) [3]. Owing to the essential nature
Concluding remarks
Nucleoside analogues are currently used for the treatment of a limited number of diseases, in particular some cancers. Recent advances in the understanding of the molecular mechanisms of adenosine transporters and their physiological roles offer the potential of therapeutic intervention in a much broader range of pathologies. Although, to date, no evidence directly links nucleoside transporters to disease pathogenesis, these proteins have a therapeutic potential that is yet to be fully realized.
Acknowledgements
We gratefully acknowledge the financial support of the MRC, the British Heart Foundation, the Wellcome Trust, the Canadian Institutes of Health Research and the Alberta Cancer Board. J.D.Y. is a Heritage Scientist of the Alberta Heritage Foundation for Medical Research, and C.E.C. holds the Canada Research Chair in Oncology. Assistance with artwork was provided by T. Lee, University of Leeds.
References (69)
Purine and pyrimidine transport in pathogenic protozoa: from biology to therapy
FEMS Microbiol. Rev.
(2005)Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney
Eur. J. Pharmacol.
(2003)Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells. ENT2 exhibits a low affinity for guanosine and cytidine but a high affinity for inosine
J. Biol. Chem.
(2000)Functional and molecular characterization of nucleobase transport by recombinant human and rat equilibrative nucleoside transporters 1 and 2. Chimeric constructs reveal a role for the ENT2 helix 5–6 region in nucleobase translocation
J. Biol. Chem.
(2002)The broadly selective human Na+/nucleoside cotransporter (hCNT3) exhibits novel cation-coupled nucleoside transport characteristics
J. Biol. Chem.
(2005)Topology of a human equilibrative, nitrobenzylthioinosine (NBMPR)-sensitive nucleoside transporter (hENT1) implicated in the cellular uptake of adenosine and anti-cancer drugs
J. Biol. Chem.
(2001)Chimeric constructs between human and rat equilibrative nucleoside transporters (hENT1 and rENT1) reveal hENT1 structural domains interacting with coronary vasoactive drugs
J. Biol. Chem.
(1998)Second-site suppression of a nonfunctional mutation within the Leishmania donovani inosine–guanosine transporter
J. Biol. Chem.
(2005)Subcellular distribution and membrane topology of the mammalian concentrative Na+-nucleoside cotransporter rCNT1
J. Biol. Chem.
(2001)Identification of amino acid residues responsible for the pyrimidine and purine nucleoside specificities of human concentrative Na+ nucleoside cotransporters hCNT1 and hCNT2
J. Biol. Chem.
(1999)
Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: different roles, different sources and different receptors
Neurochem. Int.
Adenosine and brain function
Int. Rev. Neurobiol.
Distinct regional distribution of human equilibrative nucleoside transporter proteins 1 and 2 (hENT1 and hENT2) in the central nervous system
Neuropharmacology
Distribution of mRNA encoding a nitrobenzylthioinosine-insensitive nucleoside transporter (ENT2) in rat brain
Brain Res. Mol. Brain Res.
Differential expression of human nucleoside transporters in normal and tumor tissue
Biochem. Biophys. Res. Commun.
Adenosine and sleep
Sleep Med. Rev.
Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study
Neuroscience
Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state
Behav. Brain Res.
Recent advances in the neurobiology of alcoholism: the role of adenosine
Pharmacol. Ther.
Ethanol increases extracellular adenosine by inhibiting adenosine uptake via the nucleoside transporter
J. Biol. Chem.
Adenosine in the spinal cord and periphery: release and regulation of pain
Prog. Neurobiol.
Distribution of antinociceptive adenosine A1 receptors in the spinal cord dorsal horn, and relationship to primary afferents and neuronal subpopulations
Neuroscience
Modulation by adenosine of Aδ and C primary-afferent glutamatergic transmission in adult rat substantia gelatinosa neurons
Neuroscience
Localization of the NBMPR-sensitive equilibrative nucleoside transporter, ENT1, in the rat dorsal root ganglion and lumbar spinal cord
Brain Res.
Regulation by equilibrative nucleoside transporter of adenosine outward currents in adult rat spinal dorsal horn neurons
Brain Res. Bull.
Anti-hyperalgesic and morphine-sparing actions of propentofylline following peripheral nerve injury in rats: mechanistic implications of spinal glia and proinflammatory cytokines
Pain
Amitriptyline enhances extracellular tissue levels of adenosine in the rat hindpaw and inhibits adenosine uptake
Eur. J. Pharmacol.
Adenosine contributes to μ-opioid synaptic inhibition in rat substantia gelatinosa in vitro
Neurosci. Lett.
Intrathecal morphine reduces allodynia after peripheral nerve injury in rats via activation of a spinal A1 adenosine receptor
Anesthesiology
Effects of nucleoside transport inhibition on long-term ex vivo preservation of canine hearts
J. Thorac. Cardiovasc. Surg.
Nucleoside analogues and nucleobases in cancer treatment
Lancet Oncol.
Cell entry and export of nucleoside analogues
Virus Res.
Potential chemotherapeutic targets in the purine metabolism of parasites
Pharmacol. Ther.
Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes
J. Biol. Chem.
Cited by (244)
Equilibrative nucleotide transporter ENT3 (SLC29A3): A unique transporter for inherited disorders and cancers
2024, Experimental Cell ResearchHow astrocytic ATP shapes neuronal activity and brain circuits
2023, Current Opinion in NeurobiologyOptimising the energetic cost of the glutamatergic synapse
2021, NeuropharmacologyViral vector-mediated gene therapy for opioid use disorders
2021, Experimental NeurologyAstroglia-specific contributions to the regulation of synapses, cognition and behaviour
2020, Neuroscience and Biobehavioral Reviews